25 September 2024
Avingtrans
Plc
("Avingtrans" or the "Group")
Preliminary results for the
year ended 31 May 2024
Avingtrans PLC (AIM: AVG), which
designs, manufactures and supplies critical components, modules,
systems and associated services to the energy, medical and
industrial sectors, is pleased to announce its preliminary results
for the year ended 31 May 2024.
Financial Highlights
· Revenue from continuing operations increased by 17.3% to a
record £136.6m (2023: £116.4m)
· Gross
Margin was stable at 32.2% (2023: 32.9%)
· Adjusted EBITDA from continuing operations was slightly
ahead of the upgraded market expectations at £14.0m (2023: £13.7m),
following planned strategic investments in Adaptix and Magnetica,
Underlying Adjusted EBITDA (excluding acquisitions) was
£16.0m
· Adjusted PBT from continuing operations was £7.3m (2023:
£9.0m), excluding acquisitions was £12.0m
· Adjusted Diluted earnings per share from continuing
operations was 18.5p (2023: 23.4p)
· Net
Debt (excluding IFRS16) as of 31st May 2024 of £6.1m
(Net Cash 31 May 2023: £13.0m)
· Final
dividend of 2.9p per share proposed, resulting in a total dividend
of 4.7p per share (2023: 4.5p)
Operational Highlights
Energy (AES)
· Revenue increased by 17.8% to £132.9m (2023
£112.8m)
· Improved result with Adjusted EBITDA up 13.5% to £17.9m (2023:
£15.5m)
· Metalcraft contract to supply the Sellafield 3M3 boxes
continues, in phase two of the programme
· Booth
commenced manufacture of HS2 door frames. Aftermarket sales
increasing strongly
· Ormandy records best result since acquisition, following
successful integration of HES/HEVAC in 2023
· Acquisition of the assets of S&P in August 2023 for £4.1m.
S&P records creditable first year result
· Two
new nuclear decommissioning contracts won by Metalcraft, worth
£14.5m combined
· HT
Luton won £2.5m defence contracts from Rolls Royce and a further
£3.0m from Forsmark
· HT Inc
won $10.0m pumps contract from TerraPower, for next generation
nuclear power station
Medical (MII)
· Revenue stable year on year at £3.7m, pending the volume
build-up of new MRI and X-ray products
· As
anticipated, LBITDA increased to (£2.8m), vs 2023: (£0.6m) as MRI
and X-ray development projects progress
· Acquisition of the remaining interest in Adaptix for a total
combined consideration of £7.2m, including absorbed and repaid
debts
· Magnetica and Adaptix both appointed first US distributor,
Televere Systems
· Strong
market pull for both businesses at trade shows, supported by
compelling sales propositions
· Adaptix equipping Scottish facility to manufacture key system
components for Vet and Ortho products
· Magnetica expanded into a bigger factory, to facilitate volume
MRI system production, starting in 2025
· Tecmag
moved into improved premises, to gear up for Magnetica and Adaptix
product sales in the USA
· Adaptix commenced sales of Vet products in the UK and USA.
Volume build-up expected in next FY
1 Adjusted to add back
amortisation of intangibles from business combinations, acquisition
costs and exceptional items
Current Trading & Outlook
· In the
quarter since 31 May 2024, the Group has performed in line with
management expectations with the momentum of FY24 continuing into
FY25
· The
Board remains confident about the current strategic direction and
potential future opportunities across our markets, though we are
mindful of turbulent market conditions
· We
will continue to refine our business by pinpointing specific
additional acquisitions as the opportunities arise, to generate
superior shareholder value, whilst maintaining a prudent level of
financial headroom.
Commenting on the results, Roger McDowell, Chairman,
said:
"We are pleased to present another solid set of results. In
many aspects, this year has been challenging, but Avingtrans has
once again performed very well as a group and exceeded market
expectations. During the year, we made prudent use of our robust
balance sheet by purchasing Slack & Parr and Adaptix, to
strengthen our positions in specialist pumps and medical imaging.
We also increased our investment in Magnetica's cutting-edge MRI
systems. We have a strong order book going into FY25, and we
anticipate growing as a Group this year thanks to favourable macro
conditions in the energy, infrastructure, and healthcare
sectors."
Enquiries:
Avingtrans plc
Roger McDowell, Chairman
Steve McQuillan, Chief Executive
Officer
Stephen King, Chief Financial
Officer
|
0135
469 2391
|
Singer Capital Markets (Nominated Adviser and
Broker)
Shaun Dobson / Alex Bond / Oliver
Platts
|
020
7496 3000
|
IFC
Advisory (Financial PR)
Graham Herring / Tim Metcalfe / Zach Cohen
|
0203
934 6630
|
Avingtrans business units
Hayward Tyler - Luton &
East Kilbride, UK and USA, China and India
Specialises in the design,
manufacture and servicing of performance-critical motors and pumps
for challenging environments.
Slack and Parr, Kegworth,
UK
Focused on the design, manufacture
and servicing of advanced precision gear metering pumps, industrial
dosing pumps and hydraulics flow divider solutions.
Energy Steel, Inc - Rochester
Hills, Michigan, USA
Provider of custom fabrications for
the nuclear industry, specialising in: OEM parts obsolescence;
custom fabrications; engineering design solutions; product
refurbishment; on-site technical support.
Stainless Metalcraft Ltd -
Chatteris, UK
|
Provider of safety-critical
equipment for the energy, medical, science and research
communities, worldwide, specialising in precision pressure and
vacuum vessels and associated fabrications, sub-assemblies and
systems.
Booth Industries - Bolton,
UK
Designs, manufactures, installs and
services doors and walls which can be tailored to be: blast &
explosion proof; fireproof; acoustically shielded; high
security/safety; or combinations of the above.
|
Ormandy Group, Bradford,
UK
Design, manufacturers and servicing
of off-site plant, heat exchangers and other HVAC (heating,
ventilation and air conditioning) products.
|
Composite Products Ltd
- Buckingham,
UK
Centre for composite technology,
parts and assemblies, serving customers in industrial
markets.
Magnetica Ltd - Brisbane,
Australia
Magnetica Limited specialises in the
development of next generation MRI technologies, including
dedicated extremity MRI systems and MRI system components.
Magnetica has successfully built and tested a compact, integrated 3
Tesla orthopaedic MRI system, demonstrating clinical-quality
imaging. Commercialisation of this system (and others) is on-going.
Magnetica's structure now includes two other business
units:
Scientific Magnetics -
Abingdon, UK
Designs and manufactures
superconducting magnet systems and associated cryogenics for a
variety of markets including MRI and provides services for Nuclear
Magnetic Resonance instruments.
Tecmag Inc - Houston,
USA
Designs, manufactures and installs
instrumentation, including consoles, system upgrades, and probes,
mainly for Magnetic Resonance Imaging (MRI) and Nuclear Magnetic
Resonance (NMR) systems.
Adaptix Ltd, Oxford &
Edinburgh, UK
Designs and manufactures novel 3D
X-ray systems, with imaging from a stationary source, at a
significantly lower dose than CT. Markets include orthopaedics,
veterinary and non-destructive evaluation.
|
|
Chairman's Statement
We are delighted to announce that
Avingtrans has performed slightly ahead of the upgraded (June)
expectations in the latest financial year. Revenue was on target,
reaching a record annual result for the Group. EBITDA (note 4) from
continuing operations was ahead of target and the modest Net Debt
position was materially below the expected outcome, post the
acquisitions of Slack & Parr and Adaptix in the period.
Encouragingly, Slack & Parr contributed a positive result to
the EBITDA outcome - commendable in its first year - and losses at
Adaptix were lower than forecast. We have a healthy order book as
we move into FY25.
Our Pinpoint-Invest-Exit ("PIE")
mantra has been the core of our strategy for many years. It was
again successfully deployed in acquiring the assets of Slack &
Parr for £4.1m. We acquired Slack & Parr, another specialist
pumps and hydraulics manufacturer, to capitalise on its global
footprint, combined with its very well-invested operational
capability, renowned brand, highly skilled workforce and large
installed base. In addition, we acquired the remaining 82% of
Adaptix for a total of £7.2m, including acquired and repaid debts
which reinforced our investments in medical imaging. Both Magnetica
and Adaptix continue to make positive progress having developed
disruptive and complementary medical imaging products, particularly
for orthopaedic applications.
In the period, the Group
restructured, with the mature engineering businesses now in one
Advanced Engineering Systems (AES) division. We continue to invest
in AES and the results again demonstrate that we are proactively
managing strong progress in this division. Notably, there were
record results at Booth and Ormandy in FY24.
In the Medical and Industrial
Imaging (MII) division, the marketing of the 3D X-ray systems at
Adaptix and the development of compact helium-free MRI systems at
Magnetica have made substantial progress in achieving key
milestones in 2024 and beyond. Magnetica's 510k application to the
FDA in the USA has been delayed until 2025, mainly driven by the
FDA's vastly increased cyber-security requirements for imaging
systems. These delays result in some increases to the
commercialisation plans and costs for the medical division, though
these costs are partially offset by R&D tax incentives and are
otherwise absorbable. We are very excited by the quality of the
imaging achieved by both MRI and 3-D X-Ray systems and we are
receiving very positive feedback from the market. Across our
business we have considerable expertise in this sector. Our only
disappointment of note being the extended US 510K approval process
for MRI.
Nevertheless, our value creation
goals are on track, supported by a conservative approach to debt,
which the Board deems to be prudent. We are optimally structured
for future exits that should maximise shareholder value.
Once again, our divisional
management teams have demonstrated agility and resilience, building
strong business platforms. Aftermarket growth in AES remained
steady, supporting our value propositions to OEM and end-user
customers. The positive sentiment in the nuclear sector and, to an
extent, in oil and gas resulted in increased orders in those
arenas. The focus on end-user access continues to drive improved
profitability and underpins our product and service
development.
The acquisition of Adaptix and our
further investment in Magnetica have firmly established the Medical
and Industrial Imaging (MII) division as a new niche imaging
systems supplier, with exciting X-ray and MRI products now well
advanced. The Board is enthusiastic about the division's potential,
expecting long-term, highly positive returns for the Group, albeit
perhaps via a different vehicle, to maximise returns.
In view of the encouraging overall
results, the Board is proposing a final year dividend of 2.9 pence
per share, resulting in a total dividend of 4.7p. With a robust
balance sheet, the Group remains vigilant in seeking shareholder
value-enhancing M&A opportunities, while also being cautious
and selective in a still uncertain world.
Finally, I extend my customary
appreciation and thanks for all Avingtrans employees' hard work and
for their dedication and resilience in navigating another
challenging, but successfully gratifying year.
Roger McDowell
Chairman
24 September 2024
Strategy and Business Review
Group Strategy
Our core strategy is to buy and
build engineering companies in niche markets, particularly where we
see turnaround and consolidation prospects; a strategy we call
Pinpoint-Invest-Exit ("PIE"), thanks to which we have had a strong
track record in returning significant shareholder value over the
past decade.
With an increased presence in our
target markets, a focus on aftermarkets, strength in depth of the
management teams and a lean central structure, the Group continues
to grow profitably - despite the effects of macroeconomic
uncertainties - and the Board is focused on seeking additions to
the Avingtrans value-add proposition.
The majority of the Group's adjusted
key financial metrics trended positively in the period, despite the
ongoing impacts of the Russia-Ukraine conflict and the related
global financial stress.
The Group is focused on the global
Energy, Infrastructure and Medical markets, which play into some of
the world's mega-trends, such as: urbanisation; an ageing
population; and an accelerating transition towards a cleaner and
healthier planet.
Divisional Strategies
Advanced Engineering Systems (AES): AES continues to strengthen its nuclear installed base,
focusing on civil, defence, and national security applications,
particularly for life extension purposes. The business also
explores opportunities in the hydrocarbon market sectors. In the
USA, Hayward Tyler ("HT") is actively developing solutions for new
nuclear technologies and other low carbon energy sources, like
concentrated solar power, to leverage the global energy supply
transition. In the period, HT secured significant contracts,
including additional pumps for the next generation nuclear
business, TerraPower, in the USA and a further life extension
equipment for the Forsmark nuclear power station in Sweden. The HT
strategy is strengthened by crucial partnership agreements with
companies like Shinhoo, expanding our product portfolio and
creating cross-selling opportunities. The acquisition of Slack
& Parr further enhances our global specialist pumps
footprint.
An important target for AES is to
establish a comprehensive offering in the nuclear decommissioning
and waste management markets, building on long-term contracts for
nuclear waste storage containers and the existing equipment
installed across the vast Sellafield site. During the period,
Metalcraft and Sellafield Limited continued with the contract to
provide high integrity stainless steel storage boxes for
Sellafield. The 3M3 ('three metre cubed') box contract is currently
valued at up to £70m and is still yet to complete. The division's
nuclear credentials were again enhanced by Booth Industries' strong
performance, expanding our market reach into Critical National
Infrastructure (CNI). Booth's multi-year contract with HS2,
initially worth £36m, is progressing well, with manufacturing of
door frames having commenced in the period. Ormandy's market
position in HVAC has been strengthened by the HES/HEVAC acquisition
in early 2023, with a resulting wider product proposition. AES
continues to benefit from a robust prospect pipeline, positioning
it well to bid for new opportunities as they arise.
Medical and Industrial Imaging (MII):
Following the Magnetica acquisition in 2021 and
the acquisition of the remaining shares in Adaptix in 2023, the
focus for the highly experienced management teams in the medical
division is to become a niche market leader in the production of
compact helium-free MRI systems and 3D X-ray systems, for
applications such as orthopaedic and veterinary imaging and
non-destructive evaluation. This is an exciting opportunity for the
Group. In support of the core strategy, the division will continue
to work on niche Nuclear Magnetic Resonance (NMR) and scientific
magnet products and services, since these are complementary
technologies. Adaptix's 3D X-ray technology is being developed in
parallel to Magnetica's MRI technology and, as we envisioned, the
two businesses are working in an increasingly complementary
manner.
Across the Group's customers, we are
capitalising on the continued pressure on aftermarket expenditure,
where operational efficiency, reliability and safety are paramount.
Customers are looking for reliable supply chain partners, to
provide long term support of both new infrastructure and legacy
installations.
Pinpoint-Invest-Exit
Continuing with our evergreen
Pinpoint-Invest-Exit strategy, Avingtrans demonstrated its
commitment by raising its stake in Magnetica to over 75% during the
period. Additionally, we successfully completed the 100%
acquisition of Adaptix, as mentioned earlier. The Group invested
over £11.3m in Magnetica and Adaptix (post acquisition) in the
period, as both businesses press ahead, to complete the development
and commercialisation of their disruptive imaging
products.
Our focus on other strategic
acquisitions was sustained, with the addition of specialist pumps
manufacturer Slack & Parr, for a total consideration of £4.1m
which is already contributing positively to Group results, after a
smooth integration process.
The Group remains confident about
the current strategic direction and potential future opportunities
across its chosen markets. Some of our market sectors (eg Nuclear)
benefitted from the global disruptions seen in the period, which
drove higher energy costs and caused national governments to review
energy security.
Markets - Energy
The global demand for energy remains
relentless and we anticipate sustained growth in the coming years.
The aftermath of the Covid pandemic spurred a push towards enhanced
efficiency and decarbonisation. However, the Russia-Ukraine
conflict subsequently raised political awareness regarding the
importance of energy security, leading to a recalibration of the
rush towards renewable energy in the short to medium term. The
energy hungry deployment of AI and growth in data centres will
further increase world energy consumption. This situation could
potentially benefit our businesses, particularly in the nuclear
sector.
End
User/Aftermarket
Operators and end-users demand a
blend of quick response through local support and a requirement to
drive improvements through equipment upgrades and modernisation.
Facilities are being operated for much longer than their intended
design lives, resulting in a strong demand for solution providers
in the supply chain to partner with end-users for the longer term.
The AES division is well positioned to grow in this end-user market
space.
Nuclear
Nuclear energy as a low carbon,
baseload power source remains an asymmetric market with respect to
future growth. Almost all the 1GW+ new build opportunities are in
Asia, with the exception of the limited UK programme. However, we
are still experiencing buoyant market segments, including
supporting the operational fleet, continued safe operation and life
extensions, decommissioning and waste management. We are also
working on the long-term development of the next generation of
technologies - i.e. Small Modular, or Advanced Generation IV
Reactors - e.g. with TerraPower and GE-Hitachi. In addition, these
segments all have the backdrop of a consolidating supply chain and
paucity of expert knowledge.
The USA still operates the biggest
civil nuclear fleet in the world, with 93 reactors generating
around 30 percent of the world's nuclear electricity. Coupled with
the heritage Westinghouse technology operating in Europe and Asia,
the division's long-standing position in this market provides
opportunities for further growth. Obsolescence and life extension
are key issues for nuclear operators worldwide and the AES division
is well positioned to support operators in addressing this critical
risk.
The UK remains pre-eminent when it
comes to decommissioning nuclear facilities and subsequent waste
management, in terms of innovative technology and overall spend.
The Group is embedded in the future manufacture of waste containers
for Sellafield and NRS (formerly Magnox) and will continue to
expand its presence in the UK and globally in the longer term. The
development of new nuclear technologies is ongoing, with activity
in the UK, South Korea, the USA and China dominating development
activity. The Group views these new technologies as an attractive
route forward for nuclear and is well positioned to develop as a
global industry partner.
Power Generation
The world continues to electrify,
with an increasing amount of primary energy going to the power
sector, which remains a key focus across the Group's AES division.
Aside from nuclear, the main sub-sectors are as follows:
·
Coal - the Group continues to
see good aftermarket activity from coal fired power stations even
though the demand for new power stations is in decline.
Opportunities still exist in India, China, Southeast Asia and
Eastern Europe. AES has optimised its product line, to take market
share and to create new opportunities - e.g. in products to remove
toxins from the exhaust stacks of power stations.
·
Gas
- natural gas, primarily in the form of combined
cycle gas turbine power plants has been a growing market space,
primarily in the West, albeit disrupted by the Russia-Ukraine
conflict. The Group continues to develop this market with both
existing and new product lines.
·
Renewables - renewable
technologies and their supporting infrastructure are a growing
market globally. The Group has a range of products that can be
applied directly to this market segment and also has expertise that
can be used to develop new products for niche parts of this market,
such as molten salt pumps for concentrated solar
applications.
Hydrocarbons
The ongoing conflict in Ukraine
resulted in a surge in European gas prices, leading to
unprecedented levels of volatility in the energy market. Our
Hayward Tyler businesses have long been associated with providing
top-notch subsea and submersible pumps and motors to the oil and
gas fields of the Norwegian Shelf. Recently, we have experienced a
boost in demand for both new equipment and aftermarket services, as
the market seeks to maximise supplies from this region. The current
situation, coupled with informed forecasts, indicates that the
demand for our products and services is likely to remain relatively
strong. This presents a promising opportunity for our business to
further capitalise on the evolving energy landscape.
Markets - Medical
The Diagnostic (medical) and
molecular imaging markets are large global sectors, dominated by a
few large systems manufacturers. The total Medical Imaging Market
is expected to reach $55.4billion by 2030 according to Grand View
Research, a compound annual growth rate of 4.9%. The largest market
is the USA, followed by Europe and Japan. The fastest growing
markets are China and India. Following the acquisition of a
majority stake in Magnetica (AUS) in 2021, we merged Magnetica with
Scientific Magnetics (UK) and Tecmag (US) and we have continued to
invest in Magnetica. In the period, we acquired 100% of Adaptix,
for £7.2m, including absorbed and repaid debt. Adaptix is an
emerging medtech leader in the field of 3D X-ray equipment. The
objective of this acquisition activity is to create innovative,
niche MRI and X-ray systems suppliers, which can address specific
parts of the market, not well served by dedicated products at
present. This includes orthopaedic and veterinary imaging. The
development paths of Magnetica and Adaptix are convergent, which
enables both businesses to benefit from efficiency and cost gains,
as well as optimising the route to market - especially in
orthopaedics. Market drivers for these segments include an ageing
global population, the rising incidence of chronic diseases and
increasing companion animal ownership.
The growing prevalence of chronic
diseases, especially in older populations, is increasing demand for
medical imaging in hospitals and other diagnostic settings.
Technical innovations, including advances in artificial
intelligence, have increased the reliability and accuracy of
medical imaging, thus driving further demand in global healthcare.
Conversely, the market is somewhat inhibited by the high cost of
current medical imaging systems.
In 2024, X-ray systems held
approximately 32% of the market share, while MRI systems accounted
for around 18%. Our estimates indicate that over 20% of all
diagnostic imaging scans are related to limbs. As a result, the
combined addressable market for Magnetica and Adaptix in medical
imaging is approximately $3 billion, in theory. However, it is
important to note that the actual addressable market is likely
smaller, since both businesses have chosen not to target sales to
hospitals. Instead, they are focusing on deploying their products
in specialised clinics, where the product attributes align closely
with the specific needs of these establishments, for imaging at the
point of care.
Additionally, both Magnetica and
Adaptix have plans to expand into other imaging markets, notably
the veterinary sector. This is in response to the lack of dedicated
products in this area, which has hindered the widespread use of
imaging systems in veterinary practices. By targeting these
specialised markets and addressing their unique requirements, both
companies aim to further grow their market share and create a
disruptive impact in the medical and veterinary imaging industries.
Notably, our strategy is to attack the markets in smaller
"point-of-care" locations, where the main players (eg GE) are not
present, since they are generally focused on whole body systems
located in hospitals. Additionally, our systems are designed to
eliminate circa 90% of the infrastructure costs, which severely
limit where whole body systems can be sited.
End
User/Aftermarket
Diagnostic imaging is dominated by a
handful of manufacturers, including GE, Siemens, Philips and Canon,
who account for circa 80% of revenue globally. These players also
dominate the aftermarket, though there are a few independent MRI
service businesses in existence. Avingtrans is not present in the
imaging aftermarket at this time.
Infrastructure and
Security
Global safety and security concerns,
as well as risk mitigation on large infrastructure projects, are
key drivers for growth at Booth and we are cultivating these
opportunities carefully. Thus far, the vast majority of Booth's
sales are in the UK but the business is building up a prospect
pipeline overseas. We have also continued to build the aftermarket
order book, with good prospects.
Threat detection standards for
baggage handling at airports and package scanning have been
tightened everywhere around the world - especially in Europe and
the USA. With many millions of bags and packages flowing across
border crossings every day, screening devices have to comply with
threat detection standards without impacting throughput. Rapiscan,
the biggest customer for Composite Products, is a market leader in
this sector, whose presence is increasing as new standards are
rolled out.
Following the acquisition of
Adaptix, we are exploring various possible security applications of
their 3D X-ray technology products as tools in various
Non-Destructive Evaluation (NDE) markets, with an estimated
addressable market of c$1.4bn.
Operations
Operational Key Performance
Indicators (KPI's) for continuing operations
|
|
2024
|
2023
|
·
|
Percentage of total continuing
revenue deriving from aftermarket (AM) sales (%)
|
38.2
|
39.5
|
·
|
Customer quality - defect free
deliveries (%)
|
89.0
|
91.3
|
·
|
Customer on-time in-full deliveries
(%)
|
73.6
|
79.9
|
·
|
Annualised staff turnover including
restructuring (%)
|
15.8
|
18.5
|
·
|
Health and Safety incidents per head
per annum
|
0.07
|
0.08
|
·
|
Environmental incidents per
annum
|
0
|
0
|
Aftermarket sales increased in value
by £6.2m (13.4%) however there was a strong return of OE Revenue
during FY24, reducing the overall AM percentage of
sales.
The defect free delivery percentage
decreased in FY24 to 89.0% (2023: 91.3%). The percentage is
typically linked to the stage/type on some of the key contracts. In
FY23, we were primarily engaged in the developing of new designs,
which have transitioned to production during FY24.
Customer quality and on time in full
(OTIF) deliveries both reduced in FY24, mainly due to the initial
poor performance at Slack & Parr, following its administration
process, leading to operational challenges, including supply
chain disruptions and internal restructuring, which affected our
ability to deliver products on schedule. Performance since
acquisition has shown steady improvement.
Annualised staff turnover fell to
15.8% in FY24 (FY23: 18.5%), mainly driven by a reduced number of
employees taking retirement (FY24: 6, FY23: 22).
H&S incidents per head per annum
was down very slightly at 0.07.
As in 2023, there were zero
environmental incidents recorded in the Group.
AES
Division - Energy and Infrastructure
The
AES division comprises: Hayward Tyler (HT), Energy Steel (ES),
Booth, Metalcraft, Ormandy and Composite Products, with Slack &
Parr being added in the period.
The division's results were
materially improved in the period, both for OE and aftermarket
sales.
For Hayward Tyler ("HT"), the main
priorities remain to strengthen its aftermarket capabilities and to
maximise opportunities in the nuclear life extension market. HT was
able to deliver a robust result in the period, the best outcome
since acquisition, with a strong order book and prospects for the
year ahead.
At HT Luton, aftermarket activities
remain the focus, including the servicing of third-party equipment.
A follow on £3m contract in Sweden with Vattenfall for the Forsmark
plant (for nuclear life extension) commenced in the period. Further
defence orders have also been received from Rolls Royce and are
being executed as planned. Hydrocarbon related orders from the UK
North Sea sector remained steady.
Regarding the HT Luton site
redevelopment, there has been limited recent progress, as the
increase in interest rates in the UK has dampened construction
interest for the time being. Therefore, we
have currently paused the sale of the site.
The HT Fluid Handling business in
Scotland has been a consistently good performer and has fitted well
into our ambitions to build a wider nuclear capability. The
business has maintained a strong order book and the Transkem
industrial mixers product line has again contributed
positively.
HT Inc in Vermont (USA) continues to
see solid order intake in the nuclear life extension market in the
USA. HT Inc's new R&D opportunities in next generation nuclear
power have made good progress, with a further $10m design and
development TerraPower contract booked in the period and
progressing to plan.
HT Kunshan (China) has developed a
healthy order book, including an improving position in the
aftermarket business, with new orders coming from Chinese
electricity producers working on reducing the environmental impact
of electricity production.
In India, the local team again
delivered a solid annual performance, as India's energy
requirements continue to expand.
Energy Steel ('ES') in Michigan
(USA) made headway in the period, though the business did suffer
from various order delays in orders, which impacted performance
this year.
Metalcraft has made good progress
with Phase 2 of the Sellafield 3M3 ("three-cubic-metres") box
contract and confirmed additional nuclear decommissioning orders of
over £14m in the period, including the first contract from NRS
(formerly Magnox). The next follow-on 3M3 box contract tender,
expected to be worth over £900m, is expected to be tendered in 2025
by Sellafield. The apprentice training centre in Chatteris
continues to build momentum.
Ormandy achieved a record
performance in the period, with a robust order book, moving into
FY25. Ormandy has made excellent progress
in building its aftermarket business, with aftermarket now
comprising 13% of revenue.
Booth Industries maintained its
strong growth trajectory. Booth has a record order book, including
the £36m order for HS2 cross-tunnel doors, which was not affected
by the HS2 phase 2 cancellation. The business completed and
installed the giant proscenium doors for "The Factory"
entertainment venue - the biggest doors ever made by Booth.
We continue to make good progress in building an
aftermarket business at Booth, where we see strong growth
potential.
Composite Products had a solid year,
boosted by new orders from Rapiscan.
Slack & Parr made a positive
start to life within the Group and, pleasingly, was able to deliver
a modest profit at EBIT in its first year with Avingtrans - a
commendable outcome. Their specialist gear
metering pumps are sought after worldwide, for a variety of
applications, including the precision production of high-end fibres
- eg spandex.
MII
- Medical Division: Magnetica and Adaptix
Magnetica, Scientific Magnetics
(SciMag) and Tecmag are working effectively together to make good
progress on our exciting development of compact, superconducting,
helium-free MRI systems entirely in-house. Magnetica was able to
exhibit its prototype system in the period and the FDA 510(k)
approval is now anticipated in H1 2025. The delay is mainly due to
significantly increased demands by the FDA regarding cyber
security. The business also appointed its first US distributor,
Televere Systems, in the period.
Our initial estimate of the
addressable MRI orthopaedic imaging market is circa £1.7bn p.a. (by
2030). This is assuming a capital sale model. Our intended longer
term "pay per scan" business model could mean that the opportunity
is significantly larger. It is more difficult to quantify other
potential market segments (e.g. veterinary imaging) at this stage
because equivalent, dedicated products do not exist. Avingtrans has
further increased its investment in Magnetica, bringing its
shareholding to over 75% of the issued share capital. We believe
that materially reducing the size and total costs of these
dedicated MRI systems, coupled with them being much easier to set
up in a variety of locations, as well as increasing the scan rate
by up to 300%, will produce a compelling sales proposition,
ratified by interest from Key Opinion Leaders at the prestigious
Radiological Society of North America conference, in
Chicago. In addition, these dedicated
systems could free-up capacity on the existing MRI system installed
base, which should be a major benefit to healthcare
organisations.
SciMag and Tecmag will rebrand in
due course, to present a seamless image for the business. However,
there is still merit in continuing with various existing products
and services at SciMag and Tecmag, so long as they do not detract
from our core vision for MRI, which holds out the prospect of
materially increasing the value of Magnetica over the coming years.
Orders for existing SciMag and Tecmag products were solid in the
period.
As noted above, Avingtrans acquired
the remaining 82% of the share capital of Adaptix, Oxford, UK in
2023. Adaptix launched its compact 3D x-ray system for orthopaedics
in the USA. Adaptix has also launched its veterinary version of the
3D x-ray product and initial orders for a non-destructive
evaluation (NDE) product were also booked in the period. We
estimate that the Total Addressable Market value of these three
segments is $6.8bn pa. Adaptix also appointed Televere Systems as
its first US distributor.
The strategies of Magnetica and
Adaptix are convergent and we see potentially large benefits in
combining their approaches to market in technology, software and
distribution channels, amongst others.
Financial Performance
Key
Performance Indicators
The Group uses a number of financial
key performance indicators to monitor the business, as set out
below (all items are "from continuing operations").
Revenue: 17.3% increase - underlying organic growth
continues
Group continuing revenue increased
to £136.6m (2023: £116.4m), with organic growth of 9% in the AES
division. Revenue included £10.3m from Slack & Parr and
Adaptix, both acquired in the period.
Gross margin: Stable despite some OEM/AM mix effects in the
year
Group gross margin reduced slightly
to 32.2% (2022: 32.9%) partly due to the relatively higher
percentage of OEM sales in the year, versus FY23.
Profit margin: Ahead of expectations
Adjusted EBITDA (note 2) increased
to £14.0m (2023: £13.7m). The result was better than expected,
given the forecast investment in the MII division. AES recorded
robust results across the division, which boosted the overall Group
performance. Slack & Parr recorded a creditable, albeit small,
positive EBIT result in its first year with the Group.
Operating profit was £5.6m (2023:
£8.0m), predominately due to £3.7m EBIT loss at Adaptix and higher
exceptional costs for acquisition and restructuring offsetting an
8% increase in AES.
Tax: Future profits and cash protected by available
losses
The effective rate of taxation at
Group level was a 24.4% (2023: 16.7%) tax charge. The utilisation
of brought forward tax losses in the UK (note 3) kept the charge
lower than expected. The tax position will be aided further in the
coming years by utilisation of losses in the UK and US. We continue
to be cautious, not recognising all of the potential trading tax
losses in the UK.
Adjusted diluted Earnings per Share (EPS) reduced due to
investments in the Medical division
Adjusted diluted earnings per share
from continuing operations (note 4) decreased to 18.5p (2023:
23.4p) reflecting the investment in Medical and higher tax charge
offsetting underlying growth in AES results. Adjusted diluted
earnings per share attributable to shareholders reduced to 18.5p
(2023: 19.9p), with FY23 including the discontinued losses for the
trading and disposal of Metalcraft China.
Basic and diluted earnings per share
attributable to shareholders from continuing activities decreased
to 11.1p (2023: 15.7p) and to 10.9p (2023: 15.3p), as above, due to
the investment in Medical and higher tax charge offsetting
underlying growth in AES results.
Funding and Liquidity: Modest net debt position, post recent
acquisitions
Net debt (including IFRS16 debt) at
31 May 2024 was £11.8m. Excluding IFRS16 debt, Net debt was £6.1m,
(31 May 2023: Net cash (including IFRS16 debt) was £9.1m and
excluding IFRS16 debt was £13.0m). The cash
flows generated from the strong underlying profits were subdued
by a £9.0m working capital outflow,
due to the delayed timing of various
contracts, working capital outflow for the
S&P and Adaptix acquisitions and increased revenue in
AES, resulting in
an operating cash inflow of £1.3m for the year (2023: £9.6m). As expected, there was significant investment
in product development during the period with £8.4m
invested, primarily in relation to
Magnetica's compact
helium-free MRI system £3.6m, Adaptix's disruptive 3D X-ray
technology £2.4m and next generation nuclear pumps at HTI
£1.8m. A further £4.0m was invested into property plant and
equipment, £0.8m lease renewals at Tecmag,
manufacturing set up at Adaptix £0.9m, alongside the initial net £1.5m cash cost of the acquisitions.
To support the significant investment in the business, the group
drew down £7.7m net of repayments from its supportive banking
partners (including new lease at Tecmag £0.7m),
leaving the Group
in a strong position to pursue its strategy. The Directors consider that the Group has sufficient
financial resources to deliver its strategy, so the Group continues
to actively look for further value enhancing
opportunities.
Dividend: Progressive dividend policy
continues
A final dividend of 2.9p per share
is proposed, making a total dividend of 4.7p per share (2023:
4.5p). The dividend will be paid on 20 December 2024, to
shareholders on the register at 8 November 2024.
People
There were no personnel changes at
Board level. However, at Board level, we have now set up an ESG
Committee, chaired by Jo Reedman.
At divisional management level, we
merged the EPM and PSRE divisions to create the AES division.
Consequently, Austen Adams, formerly the managing director of the
PSRE division, assumed leadership of this newly integrated
division. The Board would like to extend its sincere best wishes
and gratitude to Mike Turmelle, the former head of the EPM
division, who has stepped down from his role and left the Company.
His contributions during his tenure at Avingtrans are highly
appreciated.
Environmental, Social and Governance (ESG)
Report
Avingtrans believe that operating in
a safe, ethical and responsible manner is at the heart of creating
sustainable value for all our stakeholders.
Environmental
As the Group is listed on the LSE
AIM market, we fall within the newly introduced Climate-Related
Financial Disclosures ("CRFDs") regime. The four pillars of this
regime are governance, strategy, metrics and targets, and risk
management.
Governance
During the financial year, the Group
established an ESG Committee. The main responsibilities of the ESG
committee are to:
· Assist
the Board in defining and regularly reviewing Avingtrans' ESG
strategy.
· Oversee the setting of objectives and KPIs for ESG matters and
ensure that key metrics are reported on.
· Develop and review regularly the policies, practices, targets
and initiatives relating to ESG activities, ensuring they remain
effective and up to date and consistent with good industry
practice.
· Provide oversight of Avingtrans' management of ESG matters and
its compliance with relevant legal and regulatory requirements,
including applicable rules and principles of corporate governance,
and applicable industry standards.
· Report
on these matters to the Board and, where appropriate, make
recommendations to the Board.
· Report
as required to the shareholders of the Company on the activities
and remit of the Committee.
Jo Reedman (Non-Executive Director)
is Chair of the ESG committee, which meets on a quarterly
basis.
Strategy
In 2021, we reassessed our approach
to sustainability, with a view of integrating a sustainability
strategy into our core business activities, aligning ourselves with
the UN's Sustainable Development Goals (SDGs). From our
sustainability assessment we identified two principal areas of
environmental focus, these are:
· Operational eco-efficiency
· Development of new technologies
Operational eco-efficiency looks at
improvements we can make at a site level, including reducing the
manufacturing footprint of our sites, investment in improvements,
and establishing a culture which promotes carbon
reduction.
Development of new technologies
allows us to benefit from opportunities designed to mitigate issues
associated with climate change. The Group can benefit from its
advanced engineering capabilities and world-class technologies to
develop new products and services that support low carbon or
reduced emissions requirements.
Risk
management
Our approach to identifying,
assessing and managing environmental risks, including climate
related risk, is embedded within our approach to risk management.
Environmental risks may present as financial or non-financial risks
depending on the extent to which their impacts can be quantified,
and how they have been classified.
Climate change and environment is a
principal risk for the Group.
Climate-related risks and
opportunities
A summary of the climate-related
risks and opportunities identified as having a potentially material
impact on the Group, and our associated controls,
includes:
Shift to
renewables
Most countries we sell into are
moving away from fossil fuels towards renewables.
Demand for our hydrocarbon range of
products could be adversely impacted. Conversely, we could see
greater opportunities for our nuclear products.
The Group has been investing in
products for next generation nuclear, including fusion, molten-salt
fast reactors, and small modular reactors.
Extreme weather
events
Disruption could be caused by a
range of events, for example, flooding, extreme temperatures, and
drought.
Extreme temperatures will increase
the energy required to heat or cool our facilities and in extreme
cases may cause site closures and a range of logistical
issues.
We have seen such issues rising
across the Group in recent years, for example record levels of smog
in Delhi, India, because of drought and industrial
emissions.
Levels of
regulation
The Group operates in a highly
regulated environment across many jurisdictions and is subject to
regulations relating to environmental factors including, but not
limited to, climate change, therefore consideration of current and
emerging regulation within our environmental management system is
key to mitigating risk. Identified regulatory risks include
energy-related taxes and the increased costs of compliance with
energy-related schemes.
Statement of carbon emissions -compliance with Streamlined
Energy and Carbon Reporting (SECR)
We report greenhouse gas Scope 1, 2
emissions in line with the Streamlined Energy and Carbon Reporting
(SECR) regulations.
Given the Group makes regular
disposals and acquisitions, we do not consider absolute carbon
emissions to be an appropriate method for tracking emissions,
instead we focus on carbon intensity ratios.
We have adopted a portfolio approach
to tracking carbon emissions. For the division operating in the
energy sector (AES) we monitor carbon emissions per £m of revenue.
The Medical division (MII) has a greater focus on product
development, so instead we focus on emissions per
employee.
Sites track their energy usage from
a number of sources, including meter readings, mileage reports, and
invoices, then converts these inputs to energy (kWh) and carbon
emissions (tCO2e) using relevant conversion factors. Conversion
factors are published by the UK Department for Environment, Food
and Rural Affairs and the US Environmental Protection Agency
(EPA).
Our energy usage and carbon
emissions are:
|
2024
|
2023
|
|
AES
|
MII
|
Group
|
AES
|
MII
|
Group
|
Scope 1:
|
|
|
|
|
|
|
Gas
|
715
|
38
|
753
|
623
|
21
|
643
|
Oil
|
427
|
-
|
427
|
386
|
-
|
386
|
Distribution
|
27
|
1
|
28
|
16
|
2
|
18
|
Company vehicle travel
|
20
|
-
|
20
|
15
|
|
15
|
|
1,190
|
39
|
1,229
|
1,040
|
23
|
1,062
|
Scope 2 - Purchased
electricity
|
1,307
|
230
|
1,537
|
843
|
203
|
1,046
|
Total emissions tCO2e
|
2,497
|
269
|
2,766
|
1,882
|
226
|
2,108
|
|
|
|
|
|
|
|
Total energy consumption mWh
|
11,684
|
755
|
12,439
|
9,459
|
544
|
10,003
|
|
|
|
|
|
|
|
Intensity metrics:
|
|
|
|
|
|
|
Average employees
|
840
|
93
|
941
|
673
|
59
|
732
|
Emissions tCO2e per employee
|
3.0
|
2.9
|
2.9
|
2.8
|
3.8
|
2.9
|
Revenue (£m)
|
132.9
|
3.7
|
136.6
|
112.8
|
3.6
|
116.4
|
Emissions tCO2e per £m of revenue
|
18.8
|
73.1
|
20.2
|
16.7
|
62.2
|
18.1
|
|
|
|
|
|
|
|
UK
proportion of:
|
|
|
|
|
|
|
Total emissions tCO2e
|
81%
|
34%
|
76%
|
79%
|
21%
|
73%
|
Total energy consumption
mWh
|
81%
|
59%
|
80%
|
77%
|
46%
|
75%
|
In compliance with the SECR
guidance, electricity emissions are based on grid averages from the
regions we operate. As entities within the Group have transitioned
to obtaining their power through renewable energy providers our
actual electrical emissions will be lower.
The AES division division's
intensity target is to reduce its tCO2e per £m of revenue. The
figures above include the Slack & Parr business which was
acquired during the financial year. Presenting on a like for like
basis:
|
2024
|
2023
|
Movement
|
Movement %
|
Total emissions tCO2e
|
2,001
|
1,882
|
119
|
6%
|
Revenue
|
122.9
|
112.8
|
10
|
9%
|
Emissions tCO2e per £m of
revenue
|
16.3
|
16.7
|
(0.4)
|
(2%)
|
On a LFL basis the Group has
delivered a 2% improvement Emissions tCO2e per £m of revenue. This
improvement has been delivered through a combination of energy
reduction initiatives, and delivery of an increased revenue without
the need to expand our manufacturing footprint.
The MII division's intensity target
is to reduce its tCO2e per employee. In the year tCO2e per employee
has reduced to 2.9 (2023: 3.8).
Integration of environmental considerations into our
Pinpoint-Invest-Exit strategy
The Group has expanded upon its
environmental due diligence procedures, which historically used to
focus on potential environmental liabilities. The focus has now
shifted towards identifying opportunities to improve business
performance through energy reduction initiatives.
We strongly believe that investing
in next generation manufacturing facilities and development of new
technologies is key to generating a sustainable business for the
long term. Demonstrating to potential buyers our environmental
credentials and technological capabilities is a key component of
our Exit strategy.
Progress in the
year
Operational eco-efficiency
A significant proportion of the
Group's energy consumption is spent heating premises over the
winter months. At some of the older facilities energy in the winter
months (December, January and February) can be as much as 4 times
higher than over summer (June, July and August). A focused effort
has been made to reduce winter energy consumption. This includes
the installation of new boilers, additional insulation, automatic
timers on heating, as well as reducing the manufacturing
footprint.
We carried out a Carbon whole life
cycle impact assessment also known as the LCA to measure embedded
carbon in some of our key products. This process was guided by the
ISO 14067 Lifecycle Carbon Assessment ("LCA") to measure and
investigate improvement opportunities that can cut carbon
emissions. On the back of this research, we have implemented a
number to our products and processes including:
· Selection of higher quality materials designed to increase the
useful life of products and reduce maintenance.
· Introduction of reusable packaging and packaging which can be
fully recycled.
· Negotiating with customers to make fewer, larger shipments of
products in order to reduce delivery emissions.
Development of new technologies
Next generation nuclear:
Molten Chloride Fast Reactor
Our US Hayward Tyler business has
been developing high-temperature molten salt pumps, destined for a
state-of-the-art Integrated Effects Test (IET) facility, under
development by Southern Company and TerraPower, to advance
development of the Molten Chloride Fast Reactor (MCFR). This is a
transformational, fourth-generation, molten salt nuclear
technology, designed to enable low-cost, economywide
decarbonization. Located at TerraPower's Everett, Washington
facility, the IET is a non-nuclear, externally heated multi-loop
system, intended to test and validate integrated operation of MCFR
systems, as well as demonstrate multiple auxiliary MCFR
functions.
Nuclear energy and decommissioning
represent 23% of the Group's revenues in the year. The Group
believe that working on next generation nuclear projects including
MCFR in the US, ITER in France, and Small Modular Reactors ("SMRs")
in the UK and the USA, will strengthen the Group's long-term
position in the nuclear industry.
Helium-free
magnets
Existing MRI systems rely on liquid
helium, to cool the superconducting magnets at the heart of each
system. Helium is a scarce, non-renewable resource, mostly obtained
as a by-product of oil extraction. Therefore, in our new compact
MRI designs, we are seeking to take advantage of the smaller system
footprint, to enable us to rely on mechanical cooling only, thus
virtually eliminating use of helium in these
systems.
An update on the status of the
progress on the MRI development can be found in Medical Division
review on page 10.
Social
Social Responsibility
It is paramount that the Group
maintains the highest ethical and professional standards across all
of its activities and that social responsibility should be embedded
in operations and decision making. We understand the importance of
managing the impact that the business can have on employees,
customers, suppliers and other stakeholders. The impact is
regularly reviewed to sustain improvements, which in turn support
the long-term performance of the business. Our focus is to embed
the management of these areas into our business operations, both
managing risk and delivering opportunities that can have a positive
influence on our business.
Employees
The Group places considerable value
on the involvement of its employees and has continued to keep them
informed on matters affecting them directly and on financial and
broader economic factors affecting the Group. The Group regularly
reviews its employment policies. The Group is committed to a global
policy of equality, providing a working environment that maintains
a culture of respect and reflects the diversity of our employees.
We are committed to offering equal opportunities to all people
regardless of their gender, nationality, ethnicity, language, age,
status, sexual orientation, religion or disability. We believe that
employees should be able to work safely in a healthy workplace,
without fear of any form of discrimination, bullying or harassment.
We have rolled-out "dignity and respect" training programs across
the Group. We believe that the Group should demonstrate a fair
gender mix across all levels of our business, whilst recognising
that the demographics of precision engineering and manufacturing
remain predominantly male, which is, to an extent, beyond our
control.
Apprenticeships and training
All larger Group locations are
running apprenticeship schemes for young people, both to act as
socially responsible employers and to optimise the demographics of
our workforce over the mid to long term.
The apprentice training school,
based at Metalcraft, Chatteris is now fully operational. We are
partnered with West Suffolk College (WSC) as the operator and
training provider at the centre, which plans to take on between 80
and 130 students each year. Construction of the centre was funded
through a £3.16 million grant from Cambridgeshire and Peterborough
Combined Authority.
The Group continues to be recognised
nationally for the strength of its apprenticeship training schemes.
At 31 May 2024, the Group had 32 apprentices in the UK.
Health, safety, and wellbeing
The Group takes H&S matters and
its related responsibilities very seriously.
As regular acquirers of businesses,
we find different levels of capability and knowledge in different
situations. A frequent investment need in smaller acquisitions is
to spread H&S best practice from other Group businesses and
bring local processes up to required standards. Larger acquisitions
usually have well developed H&S processes and we seek to learn
from these in other business units.
Employee equality, welfare and
engagement are critical for developing our key asset. We focus on
pro-active actions, including, internal training, certifications,
and employee engagement through listening, survey and
involvement.
Our Health and Safety KPIs can be
found in the key performance indices section of the strategic
report (page 9). Health and Safety incidents per head per annum
fell to 0.07 in the year (2023: 0.08). There were 68 incidents in
the year requiring first aid or hospital attention. Excluding the
new acquisition incidents per head per annum would have remained
flat at 0.08. At Board level, Les Thomas has H&S oversight and
he conducts inspections with local management, as
appropriate.
During the year, there have been no
fatalities or serious injuries at any of our sites.
Ethical policy
The Group complies with the Bribery
Act 2010. We do not tolerate bribery, corruption or other unethical
behaviour on the part of any of our businesses or business partners
in any part of the world. Employee training has been completed in
all areas of the business to ensure that the Act is complied
with.
Outlook
Avingtrans is a niche engineering
market leader, principally in the Energy and Medical and Industrial
sectors, with a successful profitable growth record, underpinned by
our tried and tested 'PIE' strategy. Recent acquisitions will
provide further opportunities for the Group to build sustainable
value for investors in resilient market niches. We will continue to
be prudent and seek to crystallise value and return capital when
the timing is right, as part of the PIE strategy implementation.
Our strategy has served us well in the current crisis and could
result in further opportunities to grow shareholder
value.
The Group continues to invest in
both of its divisions, with a particular focus on the global energy
and medical markets, to position them for maximum shareholder
value, via eventual exits in the years to come. Magnetica's MRI
product development is progressing well, albeit delayed by
additional FDA requirements. The expected launch of the orthopaedic
product is now anticipated in the first half of 2025, subject to
FDA approval in the USA. This activity is fully complemented by the
acquisition of Adaptix and its disruptive 3D X-ray technology, with
products addressing the orthopaedic, veterinary and non-destructive
evaluation markets. The Slack & Parr acquisition is progressing
well and we anticipate a strong recovery in profit there over the
next two years. As anticipated, the Group is now in a modest net
debt position, following recent acquisitions. Our value creation
targets continue to be accomplished as planned and are underpinned
by our conservative approach to debt.
The AES division has a strong
emphasis on the thermal power, nuclear and hydrocarbon markets and
aftermarkets. The MII division is focused on compact, helium-free
MRI systems and compact point of care 3D X-ray systems, which the
Board believes could create significant future shareholder value.
To drive profitability and market engagement, each division has a
clear strategy to support end-user aftermarket operations,
servicing its own equipment and (where pertinent) that of third
parties, to capitalise on the continued market demand for
efficient, reliable and safe facilities.
The Russia-Ukraine conflict is still
a risk factor. However, we have taken effective cost and impact
mitigation actions, to limit any potential downside and we will
continue to be vigilant.
Despite the on-going global
macroeconomic uncertainty, our markets continue to develop and
M&A opportunities remain a priority for us. Businesses like
ours can command high valuations at the point of exit. The Board
remains cautiously confident about the current strategic direction
and potential future opportunities across our markets. We will
continue to refine our business by pinpointing specific additional
acquisitions as the opportunities arise, to create superior
shareholder value, whilst maintaining a prudent level of financial
headroom, to enable us to endure any subsequent
headwinds.
The Strategic Report was approved by
the Board and signed on its behalf by:
Roger McDowell
|
Steve McQuillan
|
Stephen King
|
Chairman
|
Chief Executive Officer
|
Chief Financial Officer
|
24 September 2024
|
24 September 2024
|
24 September 2024
|